Skip to Content
Merck
All Photos(1)

Key Documents

MAB8661

Sigma-Aldrich

Anti-Influenza B Antibody, nucleoprotein, clones B2, B4 Blend

ascites fluid, Chemicon®, from mouse

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

ascites fluid

antibody product type

primary antibodies

clone

B2, monoclonal
B4, monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

immunofluorescence: suitable

isotype

IgG

shipped in

wet ice

Specificity

Recognizes all subtypes of Influenza B. Blend of two clones that recognize the nucleoprotein antigen.
No cross-reactivity to influenza A, parainfluenza 1, 2 or 3, adenovirus or RSV.

Immunogen

Influenza Blend.

Application

Anti-Influenza B Antibody, nucleoprotein, clones B2, B4 Blend detects level of Influenza B & has been published & validated for use in IF.
Indirect immunofluorescence at 1:100.

Final working dilutions must be determined by end user.
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral

Physical form

Ascites fluid with 0.1% sodium azide as a preservative.
Unpurified

Storage and Stability

Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Analysis Note

Control
Influenza Control Slides, Catalogue Number 5010-5

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Genetic variability of human metapneumovirus isolated from Chilean children, 2003-2004.
Carola Escobar,Vivian Luchsinger,Danielle Bruna de Oliveira,Edison Durigon et al.
Journal of Medical Virology null
Paulina Koszalka et al.
Antiviral research, 164, 91-96 (2019-02-17)
Baloxavir Marboxil (BXM) is an influenza polymerase inhibitor antiviral that binds to the endonuclease region in the PA subunit of influenza A and B viruses. To establish the baseline susceptibility of viruses circulating prior to licensure of BXM and to
Ching-Ping Tsai et al.
Influenza and other respiratory viruses, 13(1), 91-105 (2018-07-12)
Influenza B viruses (IBVs) have never been isolated from natural-infected pigs in clinical cases, although the susceptibility of domestic pigs to experimental IBV infections had been confirmed as well as IBV-specific antibodies were detected from pigs under natural and experimental
Holly C Simmons et al.
PLoS biology, 21(12), e3002415-e3002415 (2023-12-21)
Antibody titers that inhibit the influenza virus hemagglutinin (HA) from engaging its receptor are the accepted correlate of protection from infection. Many potent antibodies with broad, intra-subtype specificity bind HA at the receptor binding site (RBS). One barrier to broad
Tina Schmidt et al.
European journal of immunology, 42(7), 1755-1766 (2012-05-16)
Antigen-specific antibodies are well characterized after vaccination with pandemic H1N1 or seasonal influenza vaccines. However, knowledge on cellular immunity toward pandemic H1N1 after vaccination and infection and cross-reactivities toward seasonal antigens is limited. Nineteen individuals were vaccinated with the pandemic

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service